AMD’s AI Advantage May Just Be Getting Started
While the spotlight often shines brightest on Nvidia, another chipmaker has been clawing its way into the conversation and could soon be in a position to steal the show.
That company is Advanced Micro Devices (NASDAQ: AMD), and it’s gearing up to report second-quarter earnings early next month.
With the stock already up 34% this year,
» Read more about: AMD’s AI Advantage May Just Be Getting Started »
Read More
Will Markets Go Up Now That Trump Is President?
Donald Trump was the first president in modern U.S. history to take office without holding a prior public office or serving in the military. This non-traditional path to the White House came with a distinctly corporate approach to economic and fiscal policy, one that both excited and unnerved investors in equal measure.
Key Points
- Trump’s focus on tax cuts,
» Read more about: Will Markets Go Up Now That Trump Is President? »
Read More
2 Stocks Buffett Is Snapping Up
Warren Buffett appeared to take a hard look at the market last year and decided he wanted to sell shares in plenty of companies, including Apple, Bank of America, and Charter Communications. His holding company, Berkshire Hathaway, even sold every share (nearly 4 million) in Floor & Decor Holdings. Overall, Buffett unloaded $133 billion in shares in 2024.
» Read more about: 2 Stocks Buffett Is Snapping Up »
Read More
Billionaire Buys Stake In Gene Therapy Stock
Ultragenyx may not have crossed your radar but it’s already in billionaire Stan Druckenmiller’s portfolio. What has he spotted in this novel therapies for rare and ultra-rare genetic diseases firm that convinced him to take a position?
Its focus on underserved patient populations, deep pipeline of innovative products, and strong track record in obtaining regulatory approvals make it an attractive long-term investment,
» Read more about: Billionaire Buys Stake In Gene Therapy Stock »
Read More
How a $300 Mistake Opened a $1 Billion Market
Novo Nordisk, the pharmaceutical giant behind weight-loss blockbusters Ozempic and Wegovy, just let a key patent on semaglutide lapse in Canada because it forgot to pay a routine maintenance fee, the pharmaceutical equivalent of forgetting to renew your car registration.
As a result, generic versions of semaglutide, the active ingredient in both drugs,
» Read more about: How a $300 Mistake Opened a $1 Billion Market »
Read MoreThe Ivy
Is AppLovin Still a Buy After Its Incredible Run?
AppLovin (NASDAQ: APP) has had the kind of year investors dream about. The mobile app marketing and advertising platform, best known for its strength in mobile gaming has seen its stock rocket more than 5x over the past 12 months, fueled by relentless revenue growth and eye-popping profits.
With a move that big,
» Read more about: Is AppLovin Still a Buy After Its Incredible Run? »
Read MoreThe Spotlight
Is Berkshire The #1 Stock to Buy In This Market?
Warren Buffett isn’t just a famous investor, he’s in a league of his own. Over nearly six decades, he’s compounded Berkshire Hathaway’s value at close to 20% annually. If you invested a meagerly $100 and let it grow at that pace for 60 years, you’d end up with over $5.6 million.
Yet despite Berkshire’s trillion-dollar size today,
» Read more about: Is Berkshire The #1 Stock to Buy In This Market? »
Read MoreThe Daily
The Commodities Feed: Bullish EIA release pushes oil higher
The oil market had a choppy session yesterday, still trying to digest the impact of Russian sanctions amid an increasingly comfortable balance as we head into 2026. However, a set of bullish numbers from the US Energy Information Administration’s (EIA) weekly inventory report ensured crude oil prices closed higher, with Brent settling 0.81% higher on the day.
» Read more about: The Commodities Feed: Bullish EIA release pushes oil higher »